Prevalence, healthcare utilization, and costs of breast cancer in a state medicaid fee-for-service program

Journal of Women's Health

Volumn 20, Issue 5, 2011, Pages 739-747

  Khanna, Rahul ^a   Madhavan, S Suresh ^b   Bhanegaonkar, Abhijeet ^b   Remick, Scot C ^b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; EXEMESTANE; FLUOROURACIL; GEMCITABINE; LETROZOLE; MEGESTROL; METHOTREXATE; PAMIDRONIC ACID; RALOXIFENE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; PREVALENCE; PRIORITY JOURNAL; SOCIOECONOMICS; UNITED STATES;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COMORBIDITY; DATABASES, FACTUAL; FEE-FOR-SERVICE PLANS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; MEDICAID; MIDDLE AGED; PREVALENCE; UNITED STATES; WEST VIRGINIA; YOUNG ADULT;

EID: 79957520303     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2010.2298     Document Type: Article

References (38)

1. American Cancer Society. Cancer facts & figures 2009. Atlanta: American Cancer Society, 2009.
2. American Cancer Society. Breast cancer: What are the risk factors for breast cancer? Atlanta: American Cancer Society, 2008.
3. Dano H, Andersen O, Ewertz M, Petersen JH, Lynge E. So-cioeconomic status and breast cancer in Denmark. Int J Epidemiol 2003;32:218-224 (Pubitemid 36622266)
4. Robert SA, Strombom I, Trentham-Dietz A, et al. Socio-economic risk factors for breast cancer: Distinguishing individual-and community-level effects. Epidemiology 2004; 15:442-450. (Pubitemid 40416932)
5. De Angelis R, Tavilla A, Verdecchia A, et al. Breast cancer survivors in the United States: Geographic variability and time trends, 2005-2015. Cancer 2009;115:1954-1966.
6. Mullins CD, Cooke JL Jr, Wang J, Shaya FT, Hsu DV, Brooks S. Disparities in prevalence rates for lung, colorectal, breast, and prostate cancers in Medicaid. J Natl Med Assoc 2004;96: 809-816. (Pubitemid 38745789)
7. Kaiser Family Foundation. Spending to survive: Cancer patients confront holes in the health insurance system. Ca-lifornia: Kaiser Family Foundation, 2009. Available at www.kff.org/insurance/7851.cfm Accessed October 30, 2009.
8. Radice D, Redaelli A. Breast cancer management: Quality-of-life and cost considerations. Pharmacoeconomics 2003;21: 383-396. (Pubitemid 36461402)
9. Barron JJ, Quimbo R, Nikam PT, Amonkar MM. Assessing the economic burden of breast cancer in a U.S. managed care population. Breast Cancer Res Treat 2008;109:367-377. (Pubitemid 351644849)
10. Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D. Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population. Womens Health Issues 2005;15: 97-108. (Pubitemid 40719064)
11. Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat 2004;83:25-32. (Pubitemid 38141890)
12. Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev 1997;18:51-76. (Pubitemid 27516400)
13. Taplin SH, Barlow W, Urban N, et al. Stage, age, co-morbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995;87:417-426.
14. Janjan N, Nattinger A, Young M. First-year treatment char-ges for early-stage vs. locally advanced breast cancer. Breast Dis 1993;6:23-27.
15. Halpern MT, Bian J, Ward EM, Schrag NM, Chen AY. In-surance status and stage of cancer at diagnosis among wo-men with breast cancer. Cancer 2007;110:403-411. (Pubitemid 47121902)
16. Ayanian JZ, Kohler BA, Abe T, Epstein AM The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med 1993;329: 326-331. (Pubitemid 23210686)
17. DuBard CA, Schmid D, Yow A, Rogers AB, Lawrence WW. Recommendation for and receipt of cancer screenings among medicaid recipients 50 years and older. Arch Intern Med 2008;168:2014-2021.
18. Collins SR, Rustgi SD, Doty MM. Realizing health reform's potential: Women and the Affordable Care Act of 2010. Issue brief (The Commonwealth Fund) 2010;93:1-18
19. U.S. Public Health Services. International classification of diseases, 9th revision, Clinical modification. 5th ed. Los Angeles: PMIC, 1996.
20. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 2008;100:888-897. (Pubitemid 351881955)
21. American Medical Association. Physicians' current proce-dural terminology\CPT 2000. Chicago: American Medical Association, 2000.
22. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98:1108-1117. (Pubitemid 44288785)
23. Maskarinec G, Dhakal S, Yamashiro G, Issell BF. The use of breast conserving surgery: Linking insurance claims with tumor registry data. BMC Cancer 2002;2:3.
24. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002;40(Suppl 8):55-61.
25. Hospital Inpatient Procedures. Hospital inpatient DRG benchmark fees search. Available at www.myhealthscore.com/frame.cfm?page = consumer/ inpfeesearch.htm Accessed October 30, 2009.
26. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
27. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: Factors influencing differences in incidence and outcome. J Natl Cancer Inst 2005;97;439-448.
28. West Virginia Cancer Registry. Cancer incidence in West Virginia. West Virginia Department of Health and Human Resources, 2008.
29. Centers for Disease Control and Prevention. State-specific prevalence and trends in adult cigarette smoking\United States, 1998-2007. MMWR 2009;58:221-226.
30. Centers for Disease Control and Prevention. U.S. obesity trends 1985-2007. Atlanta: Centers for Disease Control and Prevention, 2009. Available at www.cdc.gov/obesity/data/trends.html Accessed October 30, 2009.
31. Mountains of Hope. West Virginia Cancer Coalition: The West Virginia cancer plan, 2nd ed. Available at www.wvcancer.com/LinkClick.aspx?fileticket = oTTBTUYq3mE%3D&tabid = 499 Accessed November 15, 2009.
32. Fried LP, Bandeen-Roche K, Kasper JD, Guralnik JM. As-sociation of comorbidity with disability in older women: The Women's Health and Aging Study. J Clin Epidemiol 1999; 52:27-37. (Pubitemid 29064271)
33. Haralson RH 3rd, Zuckerman JD. Prevalence, health care expenditures, and orthopedic surgery workforce for mus-culoskeletal conditions. JAMA 2009;302:1586-1587.
34. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM-IV disor-ders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 2005;62:617-627. (Pubitemid 40973437)
35. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75 (Pubitemid 46360343)
36. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics, 2007 fact sheet. Be-thesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2008. Available at diabetes.niddk.nih.gov/DM/PUBS/statistics/Accessed November 20, 2009.
37. American Cancer Society. Hormone therapy. Atlanta: American Cancer Society; 2009. Available at www.cancer.org/docroot/cri/content/cri-2-4-4x- hormone-therapy-5.asp Accessed November 20, 2009.
38. Chirikos TN. Economic impact of the growing population of breast cancer survivors. Cancer Control 2001;8:177-183. (Pubitemid 32319376)